A deep dive into BTK degraders for the treatment of CLL

52 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, takes a deep dive into the use of BTK degraders for the treatment of chronic lymphocytic leukemia (CLL). He discusses the mechanism of action, agents in development, associated toxicities, and how these agents may change the CLL treatment landscape. This interview was recorded via an online conference call with The Video Journal of Hematology and Hematological Oncology (VJHemOnc).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Categoria
Oncology
Commenta per primo questo video.

Prossimo